688197 首药控股
2026/03 - 三个月2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)-2.244-17.303-23.163-16.662-28.777
总资产报酬率 ROA (%)-1.930-15.038-20.836-15.391-25.610
投入资产回报率 ROIC (%)-2.201-17.062-23.029-16.570-28.483

边际利润分析
销售毛利率 (%)100.00096.93098.95697.87199.371
营业利润率 (%)-53.896-1,493.787-5,376.314-3,548.333-9,518.597
息税前利润/营业总收入 (%)-53.849-1,492.472-5,511.391-3,911.122-10,613.206
净利润/营业总收入 (%)-53.896-1,486.393-5,376.400-3,548.792-9,512.739

收益指标分析
经营活动净收益/利润总额(%)117.414160.983106.795107.506114.578
价值变动净收益/利润总额(%)-18.455-12.763-8.186-3.827-0.655
营业外收支净额/利润总额(%)0.000-0.4970.0020.013-0.062

偿债能力分析
流动比率 (X)6.8926.9017.05410.89813.495
速动比率 (X)6.8646.8717.02410.89513.469
资产负债率 (%)13.91214.03612.2768.1977.137
带息债务/全部投入资本 (%)0.6990.6800.5730.2210.485
股东权益/带息债务 (%)14,033.79914,421.43017,304.74145,149.97320,485.261
股东权益/负债合计 (%)618.813612.471714.5811,119.9701,301.084
利息保障倍数 (X)-1,159.845245.53440.82810.7949.644

营运能力分析
应收账款周转天数 (天)8.1678.7808.3210.000374.343
存货周转天数 (天)--4,391.23216,031.7384,113.77458,806.566